Crinetics Pharmaceuticals Reports First Quarter 2022
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...
Source: globenewswire.com
Stay updated with breaking news from Ascending Dose Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated...